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Abstract 
Migraine is a disabling brain disorder involving abnormal trigeminovascular activation and sensitization. 
Fasting or skipping meals is considered a migraine trigger and altered fasting glucose and insulin levels 
have been observed in migraineurs. Therefore peptides involved in appetite and glucose regulation 
including insulin, glucagon and leptin could potentially influence migraine neurobiology.  We aimed to 
determine the effect of insulin (10U.kg-1), glucagon (100µg.200µl-1) and leptin (0.3, 1 and 3mg.kg-1) 
signaling on trigeminovascular nociceptive processing at the level of the trigeminocervical-complex and 
hypothalamus. Male rats were anesthetized and prepared for craniovascular stimulation. In vivo 
electrophysiology was used to determine changes in trigeminocervical neuronal responses to dural 
electrical stimulation, and phosphorylated extracellular signal-regulated kinases 1 and 2 (pERK1/2) 
immunohistochemistry to determine trigeminocervical and hypothalamic neural activity; both in 
response to intravenous administration of insulin, glucagon, leptin or vehicle control in combination 
with blood glucose analysis. Blood glucose levels were significantly decreased by insulin (p<0.001) and 
leptin (p<0.01) whereas glucagon had the opposite effect (p<0.001). Dural-evoked neuronal firing in the 
trigeminocervical-complex was significantly inhibited by insulin (p<0.001), glucagon (p<0.05) and leptin 
(p<0.01). Trigeminocervical-complex pERK1/2 cell expression was significantly decreased by insulin and 
leptin (both p<0.001), and increased by glucagon (p<0.001), when compared to vehicle control. 
However, only leptin affected pERK1/2 expression in the hypothalamus, significantly decreasing pERK1/2 
immunoreactive cell expression in the arcuate nucleus (p<0.05). These findings demonstrate that insulin, 
glucagon and leptin can alter the transmission of trigeminal nociceptive inputs. A potential 
neurobiological link between migraine and impaired metabolic homeostasis may occur through 
disturbed glucose regulation and a transient hypothalamic dysfunction. 
Keywords: Glucose, appetite, migraine, trigeminovascular activation, headache, pERK1/2 
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List of Abbreviations 
ARC – hypothalamic arcuate nucleus 
BBB – blood brain barrier 
CNS – central nervous system 
CSD - cortical spreading depression 
DMN – hypothalamic dorsomedial nucleus 
DMH – dorsomedial hypothalamic area 
ERK1/2 - extracellular signal-regulated kinase 1/2 
LRP1 - lipoprotein receptor-related protein 1 
MAP -mitogen-activated protein 
MMA – middle meningeal artery 
ObRb - long form of the leptin receptor 
pERK1/2 – phosphorylated extracellular signal-regulated kinase 1/2 
PVN – hypothalamic paraventricular nucleus 
TCC – trigeminocervical complex 
TNC – trigeminal nucleus caudalis 
VMH – ventral medial hypothalamic area 
WDR - wide dynamic range 
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Highlights 
- Insulin and glucagon inhibit trigeminal nociception 
- Inhibition by leptin is dose dependent suggesting potential multiple targets 
- Insulin, glucagon and leptin directly modulate pERK1/2 expression within the TCC 
- TCC neurons are glucose-responsive, potentially linking blood glucose levels to pain 
processing  
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INTRODUCTION 
Migraine is a severe and disabling brain condition (Goadsby et al., 2002), characterized by 
attacks of unilateral throbbing head pain, with hypersensitivity to movement, visual and 
auditory inputs (Headache Classification Committee of the International Headache Society, 
2013). Approximately one-third of migraine patients suffer attacks that are associated with 
cortical perturbations, namely migraine aura (Charles, 2013). Additional symptoms in the 
premonitory phase, such as changes of appetite, thirst, tiredness, irritability and reduced 
concentration, can precede the headache by up to 48 hours (Giffin et al., 2003).  
Migraine pathophysiology is thought to involve activation and sensitization of 
trigeminovascular nociceptive pathways that innervate the cranial vasculature, and activation 
of hypothalamic and brain stem nuclei (Akerman et al., 2011). In addition, some studies report 
that inducing cortical spreading depression (CSD), the animal correlate of aura in humans, can 
also activate the trigeminovascular system and therefore, the authors suggest migraine can 
originate outside the TCC (Moskowitz and Cutrer, 1993; Zhang et al., 2011). Migraine attacks 
can start centrally in the brain as evidenced by hypothalamic changes (Denuelle et al., 2007; 
Maniyar et al., 2014) and trigeminocervical complex (TCC) alterations (Stankewitz et al., 2011) 
during the pre-ictal phase. The migraine brain is extremely susceptible to perturbations of 
internal and external cues and their alteration likely leads to activation of the pain processing 
trigeminovascular system that includes the pseudounipolar trigeminal ganglion and its afferent 
projections to the trigeminal nucleus caudalis (TNC) and C1 and C2 regions in the medullary and 
cervical spinal cord (the TCC), and its peripheral afferent projections mainly from the 
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ophthalmic division of the trigeminal nerve to the cranial blood vessels including the pain-
sensitive dura mater (Akerman et al., 2011). 
 
Fasting or skipping meals is one of the most consistently reported migraine triggers in 
susceptible individuals and appetite change is reported during the premonitory phase (Blau and 
Cumings, 1966; Giffin et al., 2003; Kelman, 2007). The hypothalamus is a major appetite center 
and imaging studies in humans show activations in the region of the hypothalamus before 
(Maniyar et al., 2014) and during migraine headache (Denuelle et al., 2008). Several studies and 
clinical observations highlight a clear association between migraine, feeding behavior and 
metabolic disorders. Clinically, some patients report loss of appetite during attacks, potentially 
via hypothalamic mechanisms (Malick and Burstein, 2001); and common premonitory 
symptoms and/or migraine triggers include hunger or skipping meals (Giffin et al., 2003), 
suggesting disruption of common regulatory networks early in the attack phase. Obesity is a risk 
factor for migraine chronification (Bigal et al., 2006) and attack frequency and severity increase 
with body mass index (Bigal et al., 2006). Moreover, a higher migraine prevalence in metabolic 
syndrome patients was demonstrated comparing to the general population (Guldiken et al., 
2009). On the other hand, there is also a potential association with eating disorders, with a high 
prevalence of migraine in woman affected by anorexia or bulimia nervosa (D'Andrea et al., 
2012). In rodents, neuropeptides like orexin and neuropeptide Y involved in the regulation of 
feeding have been proposed to regulate the trigeminovascular system (Hoffmann et al., 2015; 
Holland et al., 2006; Martins Oliveira et al., 2016). Therefore, the gut-brain pathway that 
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enables the communication between the endocrine system and CNS may underlie the observed 
interaction of appetite regulation, glucose homeostasis and migraine (Figure 1).  
Insulin is a dipeptide hormone secreted by the β-cells of the pancreatic islets of Langerhans and 
maintains normal blood glucose levels by facilitating cellular glucose uptake, regulating 
carbohydrate, lipid and protein metabolism (Wilcox, 2005). The insulin-secreting β-cells, which 
respond to a rise in extracellular glucose with membrane depolarization, are the best 
understood glucose-sensing excitable cells (Burdakov et al., 2005). Headache is associated with 
high fasting glucose blood levels and migraine is specifically associated with higher insulin 
levels, after fasting and after the oral glucose tolerance test (Bernecker et al., 2010; Cavestro et 
al., 2007; Rainero et al., 2005). In addition, a significant prevalence of insulin resistance has 
been observed in chronic migraineurs (Fava et al., 2013). Glucagon is a polypeptide synthesized 
and secreted from pancreatic α-cells, the levels of which increase during meals creating 
postprandial satiety (Geary, 1990). Glucagon has been previously administered in migraineurs 
resulting in a lowered hyperglycemic effect compared to controls (De Silva et al., 1974), 
suggesting a defect or failure of mechanisms which normally counteract hypo- and 
hyperglycemia in migraineurs. Leptin, a peptide hormone mainly secreted by white adipocytes, 
crosses the blood-brain barrier (BBB) (Friedman and Halaas, 1998) and activates neurons in the 
paraventricular nucleus (PVN), arcuate nucleus (ARC), ventromedial hypothalamic (VMH) and 
dorsomedial hypothalamic (DMH) areas. Of particular interest lipoprotein receptor-related 
protein 1 (LRP1), which regulates leptin signaling and energy homeostasis (Liu et al., 2011), has 
been identified as a migraine risk variants in several genome-wide association studies (Chasman 
et al., 2011; Freilinger et al., 2012).  
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As these are the major peripheral hormones regulating glucose homeostasis both systemically 
and centrally, it is important to investigate their actions within the trigeminovascular system. In 
this study, we first measured blood glucose levels following systemic administration of insulin, 
glucagon and leptin throughout a 60 minute cohort. Using a valid animal model to study 
migraine pathophysiology (Bergerot et al., 2006; Messlinger and Ellrich, 2001), we then 
administered the same peptides and performed in vivo electrophysiological recordings within 
the TCC following dural-evoked nociceptive trigeminovascular activation.  
Given that in some migraineurs appetite is altered and glucose metabolism might be impaired, 
the question remains as to whether peripheral signals are able to modify the activity of TCC and 
hypothalamic neurons and if these neurons are sensitive to systemic glucose changes. Parts of 
this work have been presented previously in preliminary form at Headache meetings (Martins-
Oliveira et al., 2014a; Martins-Oliveira et al., 2014b; Martins-Oliveira et al., 2013) 
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MATERIAL AND METHODS  
General 
All experiments were conducted in agreement with the guidelines of Institutional Animal Care 
and Use Committee (UCSF) and the UK Home Office Animals (Scientific Procedures) Act 1986, 
and in agreement with the ARRIVE guidelines and the guidelines of the Committee for Research 
and Ethical Issues of International Association for the Study of Pain (Zimmermann, 1983). 
Animals were maintained under standard conditions with food and water available ad libitum. 
 
Drugs. Male Sprague Dawley rats were tested with human insulin (10U.kg-1; NovolinR, 
NovoNordisk), glucagon (100µg.200µl-1; Sigma-Aldrich) or rat recombinant leptin (0.3, 1 and 
3mg.kg-1; Sigma-Aldrich). All drugs were dissolved in sterile water, which was additionally used 
as vehicle control in the sham group. Doses were chosen based on previous studies 
demonstrating hypothalamic activity following peripheral administration (Elias et al., 2000; 
Mighiu et al., 2013) and the induction of only mild hypoglycemia or transient hyperglycemia 
prevented any neuronal damage as is seen with extremely low or high blood glucose levels 
(Auer, 2004). Regarding insulin, in preliminary studies, we have tested different doses of Insulin 
(3U.kg-1, 5U.kg-1 and 20U.kg-1; data not shown) to optimize mild hypoglycemia in our animal 
model. We thus decided to test the 10U.kg-1. 
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Blood glucose levels 
The effect of intravenous treatment with insulin (10U.kg-1), glucagon (100µg.200µl-1) and leptin 
(1mg.kg-1) or sham control (0.2-0.3ml sterile water) on blood glucose levels was studied (n=6 
per group). Briefly, adult male Sprague Dawley rats (275–365g; n=24) were anesthetized with 
5% (v/v) isoflurane (Abbott Laboratories, USA) for induction, cannulation of one femoral artery 
and both femoral veins for blood pressure measurement, maintenance anesthesia and drug 
infusion, respectively. Anesthesia was maintained with propofol (PropoFlo, 25–30 mg.kg-1.h−1, 
i.v. infusion). Following a 60 minute rest period, drugs were infused over 2 minutes and 
physiological monitoring (body temperature, blood pressure, respiratory rate, etc), was 
performed through 60 minutes, as well as quantification of blood glucose levels using tail vein 
blood samples and a glucometer (Freestyle Lyte, Abbott Diabetes Care, USA) at specific time-
points: before surgery, before infusion of drugs and at 15, 30, 45 and 60 minutes post infusion.  
 
In vivo electrophysiology 
The surgical preparation and recording setup has been reported in detail recently (Akerman et 
al., 2013). Briefly, male Sprague Dawley rats (267–386g, n=47) were anesthetized with sodium 
pentobarbitone (60mg.kg−1, i.p.) for induction and anesthesia maintained with a propofol 
solution (PropoFlo, 25–30mg.kg-1.h−1, i.v. infusion). Body temperature, respiratory rate, end-
tidal CO2 and blood pressure were continuously monitored. After placement in a stereotaxic 
frame rats were ventilated with oxygen-enriched air (2–2.5ml, 80–100strokes/minute). 
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To access the dura mater and middle meningeal artery (MMA), a craniotomy was performed 
with a saline-cooled drill and the underlying dura mater covered in mineral oil. To access the 
TCC, muscles of the dorsal neck were separated, a cervical laminectomy performed and the 
dura mater incised to expose the brainstem at the level of the caudal medulla oblongata. A 
piezo-electric microelectrode positioner was used to locate the optimal recording site within 
the TCC. After completion of the surgery, animals were left to stabilize for at least 60 minutes 
before recordings. 
 
Following removal of the parietal bone a bipolar stimulating electrode connected to a stimulus 
isolation unit was placed on the intact dura mater adjacent to the MMA for electrical 
stimulation of the perivascular afferents of the trigeminal nerve (Fig. 2A). Stimulation of 
primary trigeminal afferents was performed with supramaximally square wave pulses 
generated by a Grass S88 stimulator. Dural nociceptive neurons in the TCC were identified via 
electrical stimuli (9–15V, 0.15-0.3ms, 0.4-0.5Hz, 20 sweeps) to the dura mater, activating 
trigeminal Aδ-fibers with approximate latencies between 3 and 20 ms; by using low stimulation 
parameters, we were only able to activate fibers in the range of Aδ-fibers. 
 
Extracellular recordings were made from neurons in the TCC, activated by dural stimulation, 
with cutaneous facial receptive fields in the ophthalmic dermatome, using tungsten 
microelectrodes (0.5-1.0 MΩ). The signal from the recording electrode attached to a high-
impedance head-stage preamplifier was fed via an AC preamplifier, band-pass filtered from 
300Hz to 20kHz, and passed through a noise eliminator (Humbug, Quest Scientific, Vancouver 
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Canada) for removal of line interference before further amplification using an AC-DC second-
stage amplifier with a gain range of x20–x90. The obtained electrical signal was then fed 
through a gated amplitude discriminator and an analog-to-digital converter and to a 
microprocessor-based personal computer using Spike 2 v5.21 software where the signal was 
processed and stored. Additionally it was fed to a loudspeaker via a power amplifier for audio 
monitoring and displayed on analog and digital storage oscilloscopes to assist isolation of action 
potentials from adjacent cell activity and noise. 
 
Neurons were characterized for their cutaneous and deep receptive fields. The receptive field 
was assessed for both non-noxious (brush) and noxious inputs (pinch). When a neuron sensitive 
to stimulation of the ophthalmic dermatome of the trigeminal nerve was identified it was 
tested for convergent input from the dura mater. 
 
Trains of 20 stimuli were delivered at 5 min intervals to assess the baseline response to dural 
electrical stimulation. Responses were analyzed using post-stimulus histograms with a sweep 
length of 100ms and a bin width of 1ms that separated Aδ-fiber-activated firing (3–20ms). 
Spontaneous activity (spikes per second, Hz) was recorded for 150s preceding the dural 
stimulation using peri-stimulus histograms. Background activity was analyzed as cumulative 
rate histograms in which neuronal activity gated through the amplitude discriminator was 
collected into successive bins. When stable baseline values of the stimulus-evoked responses 
were achieved (average of 3 stimulation series) and cutaneous and deep receptive field inputs 
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from the ophthalmic division of the trigeminal nerve were obtained, responses were tested for 
up to 60 minutes following intervention. 
 
TCC neuronal responses to electrical dural afferent stimulation were tested with human insulin 
(10U.kg-1), glucagon (100µg.200µl-1) or rat recombinant leptin (0.3, 1 and 3mg.kg-1). Sterile 
water was used as vehicle in all experiments. 
 
At the end of each experiment animals were euthanized by a lethal dose of pentobarbital and 
phenytoin sodium and an electrothermolytic lesion was made in the TCC (4-6µA for 60 sec) to 
confirm the location of the recording electrode. The spinal cord was removed, serial 40µm thick 
coronal sections were cut, stained with thionin and visualized under the light microscope 
(Axioplan Microscope; Carl Zeiss) (Paxinos and Watson, 2005). All analyses were conducted on 
the TCC, which includes the trigeminal nucleus caudalis and the upper two cervical spinal levels. 
 
Immunohistochemistry 
Using the same cohort of animals of blood glucose measurements, we studied the effect of 
intravenous treatment with insulin (10U.kg-1), glucagon (100µg.200µl-1) and leptin (1mg.kg-1) or 
sham control (0.2-0.3ml sterile water) on pERK1/2 expression within the TCC and the 
hypothalamus. At the end of each experiment, animals were euthanized with pentobarbital 
sodium (60mg/kg, i.v.; Euthatal®, 20% w/v, JML) and perfused with 250ml of heparinized (1%) 
phosphate-buffered saline (PBS) through the ascending aorta, followed by 300ml of a fixative 
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solution containing 4% paraformaldehyde in 0.01M phosphate buffer, pH 7.4. The brain and 
upper spinal cord were removed, immersed in the same fixative for 2-4h followed by 30% 
sucrose in 0.01M PBS and 0.01% sodium azide, at 4°C, and sliced at 40μm in coronal orientation 
on a cryostat. Tissue was then processed for free-floating immunohistochemistry. One in four 
sequential transverse brain sections containing the hypothalamus and the TCC from each rat 
were collected, washed, blocked and incubated with a rabbit antiserum against the 
phosphorylated ERK1 and ERK2 isoforms (pERK1/2; 1:1000; 48 hours at 4-8ºC: Neuromics, USA). 
Immunodetection was achieved with a biotinylated swine anti-rabbit antiserum (1:200; 1 hour; 
Dako, Denmark), followed by an ABC solution (1:200, 1 hour; ABC Elite kit, Vector Laboratories, 
UK) and a colorimetric reaction with 3,3-diaminobenzidine tetrahydrochloride (DAB) in 0.05M 
Tris-HCl buffer containing 0.003% hydrogen peroxide. Sections were then washed in PBS, 
mounted on gelatin-coated glass slides, cleared in xylene, cover-slipped with Eukitt® and 
analyzed by light microscopy. Histological delineation of the TCC and the hypothalamus was 
made using the rat brain atlas (Paxinos and Watson, 2005).  
 
The expression of pERK1/2 was identified by the accumulation of a brown labelling for DAB in 
cell bodies, as described (Cruz et al., 2005). For data presentation, TNC, C1 and C2 were plotted 
together as TCC and included an average of 35 sections per animal. Quantification of the 
expression of pERK1/2 in the TCC (laminae I-V) was performed by visual counting using an 
optical light microscope (Axioplan Microscope; Carl Zeiss). Values of pERK1/2 staining are 
expressed as the median per animal across all the sections analyzed.  
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In the hypothalamus, we saw patterns of pERK1/2 labelling which consisted of a brown 
precipitate in perikarya and dendrites of neurons in the ARC, PVN and caudal dorsomedial 
nuclei (DMN). The PVN was divided in levels according to bregma, level I (-1.08mm and -
1.20mm; 1-3 sections per animal, n=22), level II (-1.44mm and -1.56mm; 1-3 sections per 
animal, n=24) and level III (-1.72mm and -1.80mm; 1-3 sections per animal, n=24). 
Quantification in the PVN was performed by visual counting and values of pERK1/2 staining are 
expressed as the average per animal. 
 
In the hypothalamic ARC and caudal DMN, a distinct pERK1/2 fiber labeling intensity was 
visually detected, thus separate quantification was performed as described (Borges et al., 2013) 
and values of pERK1/2 staining were expressed as optical density ratio using the free access 
software (ImageJ 1.49v). Hypothalamic ARC was divided in four levels according to bregma: 
level I (-1.72mm, -1.80mm and -1.92mm; 2 sections per animal, n=23), level II (-2.16mm, -
2.28mm and -2.40mm; 1-2 sections per animal, n=24), level III (-3.00mm, -3.12mm and -
3.24mm; 2 sections per animal, n=24) and level IV (-3.60mm, -3.72mm and -3.84mm; 2 sections 
per animal, n=23). The caudal DMN was selected according to bregma (-3.60mm, -3.72mm and 
-3.84mm; 2 sections per animal, n=23).  
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Quantification was performed using a blinded method and we only quantified pERK1/2 labelling 
on one side. As leptin, insulin and glucagon were given systemically we would anticipate that 
labelling would be similar on either side. However, for the purposes of side consistency with 
respect to the blood glucose assay/immunohistochemistry experimental group (no unilateral 
noxious stimulus) and the experimental group of stimulus evoked electrophysiology (different 
animals used in each group), a mark was made in the hypothetical contralateral side (to 
stimulus from electrophysiology studies) of the brain/spinal cord before sectioning and 
quantifications were performed in the hypothetical ipsilateral side.  
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS 22.0 software. Regarding electrophysiology 
experiments, data collected for Aδ-fibers represent the normalized data for the number of cells 
firing over a 10ms time period in the region 4–20ms post-stimulation over the 20 sweeps, and 
expressed as mean ± SEM. Spontaneous activity was measured in cell firings per second (Hz). In 
order to compare electrophysiology data with the blood glucose levels experimental group 
(baseline and 4 time-points), neuronal recording responses were averaged for 5, 10 and 15 
minutes (shown as 15 minutes time-point), as well as for 20, 25 and 30 minutes (shown as 30 
minutes time-point). For electrophysiology and blood glucose experiments, to detect whether 
there was a significant effect over time we used ANOVA for repeated measures with Bonferroni 
post-hoc correction for multiple comparisons. If Mauchly's test of sphericity was violated, 
appropriate corrections to the degrees of freedom were made according to Greenhouse–
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Geisser (Field, 2013). Student's paired t-test (two-tailed) was used for post-hoc analysis of 
individual time points comparing to pre-injection values, using the average of the three 
baselines for electrophysiology data. For immunohistochemistry, we first tested normality of 
the four groups using the Kolmogorov-Smirnov test within a region of interest. According to the 
nature of data, we either used one-way ANOVA with Bonferroni post-hoc correction for 
multiple comparisons and independent Student's t-test (two-tailed) was used for comparison 
with sham control group (data expressed as mean ± SEM); or used Kruskal-Wallis test with 
Monte Carlo exact test post-hoc correction (CI of 95%) and Mann Whitney U test for 
comparison with sham control group (data are reported as a median with interquartile, 25%,-
75% ranges), where a Bonferroni post-hoc correction was applied.  
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RESULTS 
Glucose metabolism  
Animals studied had a mean body weight of 289±3.3g and were provided with water and food 
ad libitum before the experiment. In all experiments, blood glucose was within physiological 
levels before surgery (6.6±0.1 mmol/L) and before injections (5.4±0.1 mmol/L). Intravenous 
administration of insulin (10U.kg-1; n=6) significantly decreased blood glucose levels 
(F1.8,9.0=91.6; p=0.000), reaching a maximum decrease of 65% (t5=20.755; p=0.000) at 60 
minutes post-injection (Fig. 3A). Glucagon (100µg.200µl-1; n=6) significantly increased blood 
glucose levels (F1.7,8.6=46.801; p=0.000), reaching a maximum increase of 94% (t5=15.960; 
p=0.000) at 30 minutes post-injection, returning to baseline levels by 60 min (Fig. 3A). Leptin 
(1mg.kg-1; n=6) significantly decreased blood glucose levels (F2.1,10.5=7.469; p=0.009), reaching a 
maximum decrease of 10% (t5=2.985; p=0.031) at 45 minutes that continued over the 60 
minute period (Fig. 4A). Sham control (n=6) had no significant effects on blood glucose levels 
throughout the 60 minute cohort (F2.1,10.7=0.395; p=0.698).  
 
In-vivo electrophysiology experiments 
Electrophysiological data 
Recordings were made from a total of 47 neuronal clusters in 47 rats (mean body weight of 
313±4g). Extracellular recordings in the TCC were made from wide dynamic range (WDR) 
neurons, responsive to dural MMA stimulation (Fig. 2A), and with cutaneous receptive fields in 
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the ophthalmic division of the trigeminal nerve. Neurons responding to dural electrical 
stimulation responded with an average latency of 10.3 ± 0.2ms (range 4 to 20 ms, an example 
of evoked neuronal firing can be seen in Fig. 2B) and hence were classified as Aδ fibers. Very 
few C-fiber latency (beyond 20 ms) responses were observed, and therefore we were only able 
to quantify Aδ-fiber responses. The majority of neurons were located in lamina V of the dorsal 
horn at the level of the cervicomedullary junction, with 4 neurons in lamina II-IV, at an average 
depth of 538 ± 26µm and the electrode placement was confirmed in all animals via an 
electrothermolytic lesion in the TCC (Fig. 2C, D). The mean ongoing spontaneous firing rate was 
30.9 ± 3.1Hz with the majority of neurons responding between 10 and 20 Hz; this is within the 
same range as that demonstrated in previous studies (Akerman et al., 2013). Intravenous 
injection of sterile water (n=6) had no significant effect on Aδ-fiber responses (F2.0,10.5=1.6; 
p=0.242) and ongoing spontaneous activity (F4,20=1.6; p=0.203) of trigeminal second-order 
neurons during the 60 minutes time period. 
Pancreatic peptides are able to modulate nociceptive evoked trigeminovascular activation  
Following the observed changes of blood glucose levels by pancreatic peptides (Fig. 3A), we 
then investigated the impact of insulin and glucagon on TCC neurons. Insulin (10U.kg-1; n=10) 
significantly inhibited dural-evoked responses (F3.0,27.4 =9.4; p=0.000), with a significant maximal 
inhibition of 15% at 30 min (t9=6.320; p=0.000; Fig. 3B). At this dose there was no significant 
effect on spontaneous neuronal firing (F4,36 =2.0; p=0.113). Glucagon (100µg.200µl
-1; n=8) 
significantly reduced nociceptive neuronal firing within the TCC (F4,28 =2.7; p=0.049; Fig. 3B). A 
significant maximal inhibition of 18% was achieved at 30 minutes post-injection (t7=2.603; 
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p=0.035). Glucagon had no significant effect on the ongoing spontaneous activity (F4,28 =0.7; 
p=0.560).  
 
Leptin shows an optimal dose effect on the nociceptive activation of the trigeminovascular 
system 
Because leptin also has the potential to reduce blood glucose levels (Fig. 4A), we investigated if 
leptin is able to modulate TCC neuronal firing by testing three doses (0.3, 1 and 3mg.kg-1). 
Leptin (1mg.kg-1; n=8) significantly reduced A-fibre responses to dural stimulation within the 
TCC (F3,21=5.3; p=0.007). Maximal inhibition of 15% was achieved at 45 minutes when compared 
with baseline (t7=2.526; p=0.039; Fig. 4B). Conversely, there was no significant effect on 
spontaneous neuronal firing (F3,21=1.2; p=0.315) with this dose. Leptin (0.3mg.kg
-1; n=7) had no 
significant effect on dural-evoked nociceptive firing in the TCC (F2.1,12.8=0.8; p=0.471) or ongoing 
spontaneous activity (F3,18=1.4; p=0.265). Leptin (3mg.kg
-1; n=8) had no significant effect on 
dural-evoked nociceptive responses (F1.7,12.2=1.3; p=0.287) and ongoing spontaneous neuronal 
activity (F3,21 =2.5; p=0.082) in the TCC. These results suggest leptin displays an optimal dose 
inhibition of dural-evoked trigeminovascular activation, as a nociceptive inhibitory response 
was only seen with 1mg.kg-1. 
Blood pressure 
In all experiments, blood pressure was kept at physiological levels (95.3±3.2mmHg) before 
injections. Intravenous administration of insulin (10U.kg-1) significantly increased mean arterial 
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blood pressure after injection, reaching a maximum increase of 16% (t9=5.719; p=0.000). Blood 
pressure values recovered to pre-injection values after 11±2 min (t9=5.801; p=0.000) post-
injection. Glucagon (100µg.200µl-1) significantly decreased the mean arterial blood pressure, 
maximally by 11% (t7=4.899; p=0.002), returning to baseline after 2±0.2 min (t7=8.039; 
p=0.000). Leptin (1mg.kg-1) significantly increased mean arterial blood pressure after injection, 
reaching a maximum increase of 7% (t7=2.834; p=0.025). Blood pressure values slowly 
recovered to pre-injection values after approximately 8±1 min (t7=4.537; p=0.003) post-
injection. Leptin (0.3mg.kg-1) and leptin (3mg.kg-1) had no significant effects on blood pressure 
(t6=0.499; p=0.636 and t7=2.319; p=0.053, respectively), likewise sterile water administration 
(t5=2.392; p=0.062). 
Immunohistochemistry 
In general, a baseline labelling was observed in control sham group and this is likely due to 
normal circadian variations in pERK1/2 expression (Goldsmith and Bell-Pedersen, 2013) or the 
result of the manipulation of the animals on the experimental day. In the TCC, there was an 
overall significant effect between groups (χ2(3)=53.647; p=0.000; Fig. 4A,B). Comparing to sham 
control animals with a median of 10 cells (range 7-13), the levels of pERK1/2 positive cells were 
significantly decreased by insulin (median=4, range 2-5; U=34.0; p=0.000) and leptin (median=2, 
range 2-4; U=11.0; p=0.000). Conversely, glucagon significantly increased pERK1/2 expression 
levels (median=18, range 12-28; U=51.5; p=0.000; Fig. 5 A, B, C). Besides of the overall increase, 
we observed a reorganization of pERK1/2 expression within laminae, most noticeable within 
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lamina III, where glucagon (median=7, range 3-10) significantly increased pERK1/2 expression 
(U=23; p=0.003) comparing to sham control (median=2, range 1-4). 
 
Hypothalamic regions 
In the hypothalamic ARC, there was an overall significant effect between groups (F3,20=5.5; 
p=0.006; Fig. 6 A,B,C). Comparing to sham control animals, pERK1/2 expression was significantly 
decreased by 24.3% following leptin administration (t10=2.856; p=0.017). However, insulin 
(t10=0.295; p=0.774) or glucagon (t10=2.160; p=0.056) had no significant effect. Moreover, in 
other hypothalamic nuclei analysed, there was no significant overall difference in the PVN 
(F3,20=2.1; p=0.127) (Fig. 6D) and caudal DMN (χ
2(3)=0.846; p=0.869). 
 
Non-hypothalamic regions 
Considering other brain areas of potential interest in the context of both appetite and pain 
pathophysiology: there was no significant overall difference between groups in the midbrain 
periaqueductal gray (χ2(3) = 3.000; p = 0.392) and no pERK1/2 expression in the ventral 
tegmental area (χ2(3)=0.000; p = 1.000). Likewise, there was no significant overall difference 
between groups in the nucleus accumbens (χ2(3)=3.000; p = 0.392). 
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DISCUSSION 
Our data demonstrates that peptides normally produced by the endocrine system and involved 
in feeding mechanisms activate pathways capable of modulating neuronal responses in the TCC 
following dural nociceptive activation. These changes are likely mediated through coordinated 
actions as part of a homeostatic feedback mechanism whose perturbation can influence the 
trigeminovascular system.  
 
Glucose homeostasis and nociceptive activation of the trigeminovascular system 
 Pancreatic peptides insulin and glucagon both inhibited nociceptive trigeminovascular 
activation, yet display opposite effects on blood glucose levels. These results suggest acute 
changes of systemic glucose levels can alter TCC nociceptive responses in healthy animals by 
perturbation of normal physiology. The insulin dose used in our study induced a mild 
hypoglycemic state, reducing blood glucose levels, which has been previously shown to 
normalize beyond 60 minutes (data not shown). Interestingly, the maximum insulin-induced 
inhibition of dural-evoked TCC neuronal firing occurred after 30 minutes. In the case of 
glucagon, blood glucose levels increased maximally at 30 minutes, which matched the 
maximum inhibition of A-fibre responses to dural stimulation, with responses no different to 
pre-injection levels by 60 minutes. Indeed, both insulin and glucagon activate a counter 
regulatory mechanism that involves a tight regulation of glucose sensing (Thorens, 2011), 
suggesting that modulation of glucose-excited or glucose-inhibited neurons in the brain 
(Karnani and Burdakov, 2011; Routh, 2002), may be a crucial interface between migraine and 
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appetite regulation. The data are consistent with a view that abnormal nociceptive 
trigeminovascular activation may be triggered by a transient dysfunction of glucose 
homeostasis. 
  
In addition, our study adds new information by confirming leptin modulation of dural-evoked 
TCC neuronal activity with an optimal dose effect. It has long been known that endogenous 
leptin-resistant mechanisms are present in obese individuals (Considine et al., 1996), and 
previous studies in migraine animal models have shown that obesity causes abnormal sensory 
processing within the trigeminovascular system (Rossi et al., 2016; Rossi et al., 2013). These 
studies and our results support the involvement of leptin in migraine pathophysiology. 
 
ERK signaling cascade in the TCC and the hypothalamus: role in nociception and energy 
homeostasis control 
Our immunohistochemistry data shows a distinct pattern of pERK1/2 expression in the TCC and 
in the hypothalamus following peripheral administration of insulin, glucagon and leptin. We 
demonstrate that insulin and leptin are able to decrease pERK1/2 cell expression in the TCC, as 
opposed to glucagon, which significantly increased pERK1/2 levels. Interestingly, there is as 
correlation between neuronal pERK1/2 expression in the TCC and blood glucose changes: both 
insulin and leptin decreased blood glucose levels and pERK1/2 expression in the TCC at 60 
minutes and glucagon increases pERK1/2 neuronal expression in the TCC at 60 minutes, 
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however inducing a transient increase in blood glucose levels. This might indicate that TCC 
neurons are glucose-responsive through the ERK signaling cascade. 
 
The pERK1/2 expression study adds further information with more precise localization of 
activated neurons in the TCC, complementing the results obtained with the electrophysiology 
assay. An interesting reorganization within the TCC laminae was observed with glucagon, 
namely an increased pERK1/2 expression in lamina III (in addition to overall laminae increased 
expression). This can be related to the considerable interlaminar communication that 
influences laminae and their sensory input (Cramer and Darby, 2014). Many of the laminae 
communicate with each other via profuse dendritic branching and the axonal projections of 
their interneurons, providing a mechanism by which incoming sensory signals may be 
processed and modulated before ascending to higher centers (Cramer and Darby, 2014). 
Perhaps, this particular pathway and its corresponding interneurons are activated to allow a 
selective response to unexpected increase of blood glucose levels. Our results demonstrate that 
insulin, glucagon and leptin directly modulate nociceptive trigeminal traffic within the TCC. 
Consequently, this pathway might be impaired in migraineurs, contributing to abnormal 
sensitive responses to glucose homeostasis regulation. 
 
Regarding the hypothalamus, we observed that pERK1/2 cell expression in the ARC was 
significantly altered between groups, but no changes were observed in the other hypothalamic 
nuclei. At the tested dose, leptin significantly decreased pERK1/2 cell expression in the ARC, yet 
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this was unaffected by insulin and glucagon. Besides being involved in a number of 
physiological effects, ERKs are associated with synaptic plasticity in the brain and spinal cord 
during induction of several pain conditions (Cruz et al., 2005). In other migraine experimental 
models, increased pERK expression has been demonstrated in the TNC and related to 
sensitization of the trigeminovascular system (Dong et al., 2015) (Zhang et al., 2013).  Generally, 
the main target region of leptin is the ventrobasal hypothalamus (Elmquist et al., 1997) and our 
study shows that leptin acts in the ARC by inhibiting pERK1/2 expression. The fact that fasting 
induces a reduction in circulating leptin levels and it is a reported trigger of migraine supports 
our results showing that leptin has an anti-nociceptive role in a migraine animal model. 
However, previous studies using the same intravenous dose of leptin, in animals fed ad libitum 
show reduced Fos protein expression in VMH, PVN and DMN (Elmquist et al., 1997) and in the 
ARC (Elias et al., 2000). This may be related to differences in the point at which perfusion was 
performed; 2h after leptin administration in previous studies and 1h here. We also observed 
pERK1/2 labeling in other hypothalamic nuclei, such as the PVN and DMN, but pERK1/2 cell 
expression was not significantly different between groups. Indeed, studies in migraine animal 
models have suggested the involvement of PVN and DMN (Malick and Burstein, 2001; Robert et 
al., 2013), while the lack of significant differences of pERK1/2 expression within the PVN or 
DMN in our study may reflect a time-course difference of activation. 
 
Fasting and skipping meals relevance as migraine trigger 
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Our study shows that TCC neurons are glucose-responsive and regardless of systemic glucose 
levels, the output is the same, ie, inhibition of A-fibre trigeminal responses to dural-
nociceptive stimulation in healthy animals. Fasting or skipping a meal for longer than the 
recommended guidelines, followed by refeeding, will rapidly shift glucose homeostasis 
pathways, and it is this sudden physiological response that is likely to trigger migraines in 
susceptible individuals. In addition, and according to the suggested insulin-resistance observed 
in migraineurs, insulin will not be able to perform its homeostatic role in glucose metabolism 
and, perhaps, will not be able to modulate nociceptive inputs. 
 
Furthermore, we have shown that peptides involved in glucose homeostasis affect A-fibre 
responses to dural stimulation, however, we cannot rule out potential effects on C-fiber neural 
responses. Ongoing spontaneous TCC neuronal firing was unaffected suggesting their action is 
nociceptive-specific. Preservation of glucose homeostasis during fasting requires a fine balance 
in glucose and appetite metabolism, including physiological feedback inhibition loops, and this 
might explain the optimal dose effect of leptin observed herein. Fasting or skipping meals has 
been consistently described as a migraine trigger and clinical studies also report perturbations 
in peptide levels in migraineurs: increased leptin and insulin levels (Bernecker et al., 2010), but 
lower serum levels interictally (Guldiken et al., 2008); and higher insulin levels compared to 
controls (Cavestro et al., 2007; Rainero et al., 2005) and a significant prevalence of insulin 
resistance in chronic migraineurs (Fava et al., 2013). Interestingly, a significant association 
between a polymorphism of five single nucleotides of the gene encoding for insulin receptors in 
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migraineurs has been found (McCarthy et al., 2001), which may cause lower insulin receptor 
activation in susceptible migraineurs. The relevance of these studies is to acknowledge that 
modulatory cross-talks between insulin, glucagon and leptin may be impaired in migraineurs. 
These results might indicate that fasting or skipping meals should not be interpreted as an 
isolated trigger of migraine, but rather part of a “cumulative triggering”, for instance along with 
dehydration, changes of sleep patterns or disruption of the stress hormones feedback loop 
within the hypothalamic-pituitary-adrenal axis. Therefore, it is the combination of triggering 
factors that increases the likelihood of a migraine attack. 
 
CONCLUSION 
Considered altogether, the data are consistent with a view that off target effects of peptides 
involved in blood glucose homeostasis may increase the predisposition to triggering migraine 
through altered feeding schedule. In addition, pharmacological pERK inhibition may constitute a 
putative tool to control nociceptive-induced mechanisms related to migraine pathophysiology 
and further studies should be considered.  Furthermore, since endocrine peptides are clearly 
involved in migraine pathophysiology, skipping meals should be taken into consideration as 
soon as the premonitory phase of the attack is identified by the migraineur. 
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Figure 1. Schematic representation of neuroendocrine signaling in healthy individuals during 
two different feeding conditions (fasting and immediate post-feeding).  
Leptin is released from adipose tissue and insulin and glucagon are release by the pancreas into 
the blood circulation. These peptides are able to cross the blood brain barrier (BBB) and act in 
the hypothalamus to regulate appetite and blood glucose levels. There is a potential 
hypothalamic output (dashed arrow) towards the trigeminocervical complex (TCC) and these 
peptides may additionally act directly at the TCC, modulating nociceptive trigeminovascular 
activation. PVN: hypothalamic paraventricular nucleus; ARC: hypothalamic arcuate nucleus; 
DMN: hypothalamic dorsomedial nucleus; CNS: Central nervous system. 
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Figure 2. Overview of the experimental setup and neuronal characteristics. 
A) Experimental setup with dural electrical stimulation and recording of neurons in the TCC. 
MMA: middle meningeal artery; TCC: trigeminocervical complex; C1: spinal cord cervical 1; TNC: 
trigeminal nucleus caudalis.  
B) An original tracing from a typical unit (second-order neurons) responding to electrical 
stimulation of the dura mater adjacent to the MMA (latencies in the Aδ-fiber range). Black 
arrow represents stimulus artefact.  
C) The location of recording sites in the TCC from which recordings of nociceptive neurons, 
receiving convergent input from the dura mater and facial receptive field, were made. The 
locations were reconstructed from lesions () and are located in laminae II –V, predominantly in 
lamina V.  
D) A histological example for the lesion mark (brown lesion as indicated by the arrow) of the 
recording site in the TCC (lamina V), marked by electrothermolytic lesion (4-6 µA for 60 sec). 
The section was counterstained with thionin.  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
33 
 
 
                                    
Figure 3. Effects of insulin and glucagon on blood glucose levels and on dural-evoked 
neuronal firing in the trigeminocervical complex (TCC). 
A) Time course changes in blood glucose levels before surgery, before administration of drugs 
and following intravenous administration of insulin (10U.kg-1) and glucagon (100µg.200µl-1) 
throughout the 60 minutes post-injection. Insulin (10U.kg-1) significantly decreased blood 
glucose levels to a maximum of 1.9 mmol/L. Glucagon (100µg.200µl-1) significantly increased 
blood glucose levels to a maximum of 10.4mmol/L at 30 minutes and returned to pre-injection 
levels at 60 minutes. Vehicle control had no effect on responses and blood glucose levels were 
kept in the physiological range of 5.4-5.5mmol/L.  
B) Time course changes in the average response of dural-evoked A-fiber trigeminal neuronal 
firing in response to insulin (10U.kg-1) and glucagon (100µg.200µl-1), which significantly 
decreased neuronal responses across the 60 minutes study. Vehicle control had no effect on 
responses.  
*p<0.05; **p<0.01; #p<0.001  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
34 
 
 
Figure 4. Effects of leptin on blood glucose levels and on dural-evoked neuronal firing in the 
trigeminocervical complex (TCC). 
A) Time course changes in blood glucose levels before surgery, before administration of drugs 
and following intravenous administration of leptin (1mg.kg-1) throughout the 60 minutes post-
injection. Leptin (1mg.kg-1) significantly decreased blood glucose levels to a maximum of 
4.7mmol/L, respectively. Vehicle control had no effect on responses and blood glucose levels 
were kept in the physiological range of 5.4-5.5mmol/L.  
B) Bar graph of the maximum effect of leptin (0.3, 1 and 3mg.kg-1) at the ‘45 minutes time 
point’ of the change from baseline of dural-evoked Aδ-fiber activity in the TCC. Leptin (1mg.kg-
1) significantly inhibited dural-evoked Aδ-fiber activity in the TCC, demonstrating an optimal 
dose effect for leptin. Vehicle control had no effect on responses.   
*p<0.05; **p<0.01; #p<0.001 
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Figure 5. Effect of intravenous administration of insulin, glucagon and leptin on pERK1/2 cell 
expression within the trigeminocervical complex (TCC). 
A) Box plots summarising pERK1/2 expression in the TCC, consisting of the trigeminal nucleus 
caudalis (TNC) and C1 and C2 dorsal horn laminae I-V. Insulin (10U.kg-1) and leptin (1mg.kg-1) 
significantly decreased pERK1/2 labeling within the TCC, as oppose to glucagon (100µg.200µl-1), 
which significantly increased pERK1/2 expression, when compared to control sham group, 60 
minutes post-injection.  
B) Photomicrographs showing the localization of pERK1/2 staining in the TCC.  
C) Photomicrograph showing pERK1/2 stained neurons in the TCC of an animal administered 
with glucagon (100µg.200µl-1). Arrows indicate cell bodies.  
*p<0.05; **p<0.01; #p<0.001 
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Figure 6. Effect of intravenous administration of insulin, glucagon and leptin on pERK1/2 cell 
expression within the hypothalamic arcuate nucleus (ARC) and paraventricular nucleus (PVN) 
A) Leptin (1mg.kg-1) significantly reduced pERK1/2 cell expression within the ARC, while insulin 
(10U.kg-1) and glucagon (100µg.200µl-1) did not significantly affect pERK1/2 expression, when 
compared to control sham group, 60 minutes post-injection.  
B) Photomicrographs showing the localization of pERK1/2 staining in the hypothalamic ARC. 
Dotted line shows the ARC nucleus; 3V: third ventricle.  
C) Photomicrograph showing the localization of pERK1/2 staining in the hypothalamic ARC of an 
animal administered with glucagon (100µg.200µl-1). Arrows indicate cell bodies; 3V: third 
ventricle.  
D) Photomicrographs displaying the localization of pERK1/2 staining in the PVN showing no 
significant difference between groups.  
*p<0.05; **p<0.01; #p<0.001 
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